Syntonix Pharmaceuticals, Inc.
About Syntonix Pharmaceuticals
Syntonix discovers and develops novel, long-acting, proprietary therapeutic products using the company’s proprietary Fc-fusion proteins and other engineered ligands which bind to specific Fc receptors. These technologies, including Syntonix’ drug delivery platform technology Transceptor™, harness the body’s natural pathways for protecting antibodies against premature destruction and for transporting antibodies across cell barriers such as those in the lungs and intestines. Syntonix focuses on using these technologies to create next generation treatments for devastating chronic diseases such as hemophilia, anemia, and autoimmune disorders. Syntonix develops selected products for specialty indications, such as hemophilia, on its own. Other products will be evaluated and commercialized through partnerships with companies with established market positions.
The company is headed by an experienced management team and has focused initially on using its proprietary technology to enhance existing drugs with proven safety, efficacy, and economic return. Syntonix currently occupies a 25,000 square foot state-of-the-art laboratory facility, including a cGMP clinical manufacturing suite, in Waltham, Massachusetts.
News about Syntonix Pharmaceuticals
27-Nov-2008 | research and development
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
Biovitrum AB and Syntonix Pharmaceuticals, Inc., a subsidiary of Biogen Idec announced that the company's FIXFc compound for the control and prevention of ...
06-Mar-2008 | research and development
Biovitrum and Syntonix begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for treatment of Hemophilia B
Biovitrum AB and Syntonix Pharmaceuticals, Inc. have obtained approval from the US Food and Drug Administration to commence a clinical phase I/IIa study of ...
08-Jan-2007 | business & finance
Biogen Idec to acquire Syntonix
Biogen Idec and Syntonix Pharmaceuticals announced that the companies have signed a definitive agreement for the acquisition of Syntonix by Biogen Idec. ...
19-Sep-2006 | business & finance
Serono and Syntonix to pursue the development of long-acting, inhaleable therapy to treat infertility
Second Agreement Between Companies Builds on Interferon-beta SynFusion Program
25-Jan-2006 | business & finance
Biovitrum and Syntonix enter agreement for the joint development and commercialization for the treatment of Hemophilia
Biovitrum AB and Syntonix Pharmaceuticals, Inc. have entered into a co-development and commercialization agreement for Syntonix' long-acting, recombinant ...